FDA Halts Rocket Pharma’s Gene Therapy Trial After Patient Death and 63% Stock Plunge
In a significant development, the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Rocket Pharmaceuticals’ mid-stage gene therapy trial following the death of a patient. The trial was evaluating RP-A501, an experimental treatment for Danon disease—a rare genetic disorder affecting heart and muscle function. The patient developed capillary leak syndrome, leading to severe complications and subsequent death.
Rocket Pharmaceuticals has voluntarily paused further dosing and is collaborating with the FDA and medical experts to investigate the incident. The company has not provided a timeline for resuming the trial.
The news had an immediate impact on Rocket Pharma’s stock, which plummeted by 63% in premarket trading, falling from $6.27 to $2.30.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
U.S. and China Reach Consensus on More Favorable Tariff Treatment for $30 Billion of Goods Each Way
-
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
-
3M, DuPont and Honeywell Must Face Firefighters’ PFAS Turnout-Gear Lawsuit
-
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
UK Opens Formal Review of AkzoNobel–Axalta $25 Billion Merger
Recommend Reading
-
![India Proposes New GMP Rules for Clinical Trial and API Manufacturing]()
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
![U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment]()
U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment
-
![The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030]()
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
![Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy]()
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
![A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization]()
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
![Business Society October 12, 2026 DOP Trend Analysis: Strongly Bullish]()
Business Society October 12, 2026 DOP Trend Analysis: Strongly Bullish
-
![Recent Polyethylene Prices Remain Under Pressure Amid High-Level Fluctuations]()
Recent Polyethylene Prices Remain Under Pressure Amid High-Level Fluctuations
-
![Business Society’s Market Outlook for MIBK on September 3, 2026: Fluctuating Trend]()
Business Society’s Market Outlook for MIBK on September 3, 2026: Fluctuating Trend
-
![Business Society October 12, 2026 Propylene Oxide Trend Analysis: Strong Consolidation (Bullish)]()
Business Society October 12, 2026 Propylene Oxide Trend Analysis: Strong Consolidation (Bullish)
-
![September Isooctanol Prices in China Surge Before Declining]()
September Isooctanol Prices in China Surge Before Declining
